

Par Pharmaceutical - Recall of treprostinil injection

- On March 12, 2024, <u>Par Pharmaceutical announced</u> a consumer-level recall of one lot of <u>treprostinil</u> injection due to the potential for the presence of silicone particulates in the product solution.
- This recalled lot was distributed nationwide to pharmacies from June 16, 2022 through October 17, 2022.

Product Description	NDC number	Lot number (Exp Date)
Treprostinil 20 mg/20 mL injection	42023-206-01	57014 (4/2024)

- Treprostinil is indicated for the treatment of pulmonary arterial hypertension to diminish symptoms associated with exercise. It is also indicated in PAH patients requiring transition from epoprostenol.
- Administration of an injectable product that contains particulate matter may result in local irritation
 or swelling in response to the foreign material. If the particulate matter reaches the blood vessels
 it can travel to various organs and block blood vessels in the heart, lungs or brain which can
 cause stroke and even lead to death. To date, Par has not received any reports of adverse events
 related to this recall.
- Anyone with the affected product on hand should discontinue use, stop distribution and quarantine
 product immediately. Patients should contact their healthcare provider if they have experienced
 any problems that may be related to using the recalled product.
- Consumers may contact Inmar (appointed company for Par) at 1-855-410-3565 for more information.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.